Helmholtz Gemeinschaft

Search
Browse
Statistics
Feeds

B cell and aquaporin-4 antibody relationships with neuromyelitis optica spectrum disorder activity

[thumbnail of Original Article]
Preview
PDF (Original Article) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
794kB
[thumbnail of Supporting Information] MS Word (Supporting Information)
1MB

Item Type:Article
Title:B cell and aquaporin-4 antibody relationships with neuromyelitis optica spectrum disorder activity
Creators Name:Bennett, J.L., Pittock, S.J., Paul, F., Kim, H.J., Irani, S.R., O'Connor, K.C., Patterson, K.R., Smith, M.A., Gunsior, M., Mittereder, N., Rees, W.A., Cimbora, D. and Cree, B.A.C.
Abstract:This post hoc analysis of the randomized, placebo-controlled N-MOmentum study (NCT02200770) of inebilizumab in neuromyelitis optica spectrum disorder (NMOSD) evaluated relationships between circulating B-cell subsets and aquaporin-4 immunoglobulin G (AQP4-lgG) titers and attacks. Among participants receiving placebo, CD20(+) and CD27(+) B-cell counts were modestly increased from the pre-attack visit to attack; plasmablast/plasma cell gene signature was increased from baseline to the pre-attack visit (p = 0.016) and from baseline to attack (p = 0.009). With inebilizumab treatment, B-cell subset counts decreased and did not increase with attacks. No difference in change of AQP4-IgG titers from baseline to time of attack was observed.
Source:Annals of Clinical and Translational Neurology
ISSN:2328-9503
Publisher:Wiley
Date:2024
Official Publication:https://doi.org/10.1002/acn3.52171
PubMed:View item in PubMed

Repository Staff Only: item control page

Downloads

Downloads per month over past year

Open Access
MDC Library